Sturlimogene erparepvec
Oncolytic virus
Evidence outlook · registrational
Uveal Melanoma: registrational readout pending
No completed mid-stage readout is on record. Registrational readout expected around 2030-01.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06581406 NCT06581406 · Metastatic Uveal Melanoma Registry: NCT06581406 | 2/3 | Overall Survival (OS) (From Day 1 up to 3 years after last dose.); Progression Free Survival (PFS) (From Day 1 up to 3 years after last dose.) 2030-01 | In progress: results expected 1 Jan 2030 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2/3 (1)
What this study did
Phase 2 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (1)
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
This drug's own stage for Uveal Melanoma: Phase 2/3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Sturlimogene Erparepvec: this drug | Phase 2/3 | Oncolytic virus | Oncolytic HSV-1 (tumour lysis and immune stimulation) | not yet graded | No reviewed efficacy summary in this indication | |
| Tebentafusp-Tebn (KIMMTRAK) | Approved | Protein / enzyme therapeutic | gp100-HLA-A*02:01 x CD3 | Partial signal | NCT03070392: Efficacy: Overall Survival (From randomization to the data cut off date of 13-Oct-2020; median follow-up duration was 14.1 months.): Tebentafusp 21.7 Months (95% CI 18.6 to 28.6) | Investigator's Choice 16 Months (95% CI 9.7 to 18.4) | |
| Darovasertib | Phase 3 | Small molecule | Protein kinase C (PKC) (inhibitor) | Partial signal | NCT05987332: Primary endpoint, PFS by blinded independent central review: median 6.9 vs 3.1 months vs investigator's choice (HR 0.42; 95% CI 0.30-0.59) (IDEAYA, 2026-04-13). | |
| Roginolisib | Phase 2 | Small molecule | PI3K-delta | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Sturlimogene erparepvec to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.